购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

Atrasentan

Rating icon 还可以
产品编号 TQ0259Cas号 173937-91-2
别名 阿曲生坦, ABT-627, A-147627, (+)-A 127722

Atrasentan (ABT-627)是内皮素受体 (endothelin receptor) 拮抗剂,能够抑制 ETA 的活性(IC50值为0.0551 nM)。

Atrasentan

Atrasentan

Rating icon 还可以
纯度: 99.08%
产品编号 TQ0259 别名 阿曲生坦, ABT-627, A-147627, (+)-A 127722Cas号 173937-91-2

Atrasentan (ABT-627)是内皮素受体 (endothelin receptor) 拮抗剂,能够抑制 ETA 的活性(IC50值为0.0551 nM)。

规格价格库存数量
1 mg¥ 412现货
5 mg¥ 993现货
10 mg¥ 1,380现货
25 mg¥ 2,820现货
50 mg¥ 3,970现货
100 mg¥ 5,7905日内发货
1 mL x 10 mM (in DMSO)¥ 1,190现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"Atrasentan"的相关化合物库

选择批次:
纯度:99.08%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
Atrasentan (ABT-627) is an endothelin receptor antagonist that can inhibit the activity of ETA (IC50 value is 0.0551 nM).
靶点活性
ETA:0.055 nM
体外活性
方法:Atrasentan (ABT-627)( 10μM,24小时) 处理PPC-1-ET 系列细胞,观察细胞生长情况。
结果:Atrasentan 处理显著增加了凋亡细胞的数量 。[2]
体内活性
方法:Atrasentan (ABT-627)(20 mg/kg ,腹膜内注射) 处理人肿瘤异种移植模型 HT29小鼠,观察Atrasentan对肿瘤缺氧的影响。
结果:Atrasentan 可以明显减少肿瘤缺氧。[1]
方法:单独Atrasentan(20 mg/kg,口服,每天)和单独多西他赛(5 mg / kg,腹腔注射,每3天一次);ABT-627(20 mg/kg,口服每天)和多西他赛(5 mg/kg,腹腔注射,每 3 天一次)治疗肿瘤异种移植模型小鼠,观察小鼠体内肿瘤生长。
结果:用 Atrasentan + 多西他赛联合治疗小鼠的肿瘤负荷和生长速率显著低于单独使用Atrasentan或多西他赛治疗的小鼠。[2]
激酶实验
Cells are incubated and treated with Atrasentan. They are then washed twice with PBS and lysed in ice-cold lysis buffer [20 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium PPi, 1 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1 μg/mL leupeptin, and 1 mM PMSF]. The extracts are centrifuged to remove cellular debris, and the protein content of the supernatants is determined using the bicinchoninic acid (BCA) protein assay reagent. Proteins (150 μg) are incubated with gentle rocking at 4°C overnight with immobilized Akt antibody cross-linked to agarose hydrazide beads. After the Akt is selectively immunoprecipitated from the cell lysates, the immunoprecipitated products are washed twice with lysis buffer and twice with kinase assay buffer [25 mM Tris (pH 7.5), 10 mM MgCl2, 5 mM β-glycerol phosphate, 0.1 mM sodium orthovanadate, 2 mM DTT] and then resuspended in 40 μL of kinase assay buffer containing 200 μM ATP and 1 μg GSK-3α/β fusion protein. The kinase assay reaction is allowed to proceed at 30°C for 30 min and stopped by the addition of Lamelli SDS sample buffer. Reaction products are resolved by 10% SDS-PAGE, followed by Western blotting with antiphosphorylated GSK-3α/β antibody. For analysis of the total amount of Akt, 40 μg of protein from the lysate samples are resolved by 10% SDS-PAGE, followed by Western blotting with anti-Akt antibody [2].
细胞实验
All three prostate cancer cell lines (LNCaP, C4-2b, and PC-3 cells) are seeded at a density of 3 × 10^3 cells per well in 96-well microtiter culture plates. After overnight incubation, the medium is removed and replaced with a fresh medium containing different concentrations of ABT-627 (0-50 μM) diluted from a 10-mM stock. After 72 h of incubation with the drug, 20 μL of MTT solution (5 mg/mL in PBS) is added to each well and incubated further for 2 h. Upon termination, the supernatant is aspirated and the MTT formazan formed by metabolically viable cells is dissolved in isopropanol (100 μL). The plates are mixed for 30 min on a gyratory shaker, and the absorbance is measured at 595 nm on a plate reader [2].
动物实验
YM598 (0.3, 1, and 3 mg/kg), atrasentan (0.3, 1, and 3 mg/kg), or 0.5% methylcellulose as vehicle is orally administered to rats with a dosing cannula. The dosing volume of the test substances and vehicle is set at 5 mL/kg. Approximately 20 min after administration of compounds, the rats are anesthetized with sodium pentobarbital, and then pithed and ventilated 30 min after dosing. Approximately 1 h after oral administration of compounds, big endothelin-1 (1 nmol/kg) is intravenously administered, and blood pressure is measured. In these two experiments, the dose of test compound that causes 50% inhibition (ID50) of the big endothelin-1-induced increase in diastolic blood pressure is determined by linear regression analysis [1].
别名阿曲生坦, ABT-627, A-147627, (+)-A 127722
化学信息
分子量510.62
分子式C29H38N2O6
CAS No.173937-91-2
SmilesC(O)(=O)[C@H]1[C@@H](N(CC(N(CCCC)CCCC)=O)C[C@@H]1C=2C=C3C(=CC2)OCO3)C4=CC=C(OC)C=C4
密度1.188g/cm3
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
DMSO: 9 mg/mL (17.63 mM)
溶液配制表
1mg5mg10mg50mg
1 mM1.9584 mL9.7920 mL19.5840 mL97.9202 mL
5 mM0.3917 mL1.9584 mL3.9168 mL19.5840 mL
10 mM0.1958 mL0.9792 mL1.9584 mL9.7920 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy Atrasentan | purchase Atrasentan | Atrasentan cost | order Atrasentan | Atrasentan chemical structure | Atrasentan in vivo | Atrasentan in vitro | Atrasentan formula | Atrasentan molecular weight